Compare IMAX & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMAX | TMDX |
|---|---|---|
| Founded | 1967 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 1997 | 2019 |
| Metric | IMAX | TMDX |
|---|---|---|
| Price | $53.31 | $88.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $44.50 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 1.8M | 975.9K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.25 | ★ 382.18 |
| EPS | 0.35 | ★ 0.61 |
| Revenue | $410,212,000.00 | ★ $605,494,000.00 |
| Revenue This Year | $9.79 | $24.25 |
| Revenue Next Year | $7.51 | $18.75 |
| P/E Ratio | $151.09 | ★ $145.21 |
| Revenue Growth | 16.47 | ★ 37.13 |
| 52 Week Low | $25.48 | $60.11 |
| 52 Week High | $54.27 | $156.00 |
| Indicator | IMAX | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 72.32 | 64.49 |
| Support Level | $34.27 | $66.64 |
| Resistance Level | N/A | $152.95 |
| Average True Range (ATR) | 1.87 | 4.31 |
| MACD | 0.38 | 1.16 |
| Stochastic Oscillator | 90.95 | 92.03 |
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.